KRAS and neoplasm: The authors identified a novel KRT8+ alveolar intermediate cell population (KACs) with KRAS mutations and stem-like features that arises prior to LUAD formation, persists after carcinogen exposure, predicts poor survival, and may serve as an intermediate in AT2-to-tumor cell transformation and a target for KRAS-directed therapies.